21 nov: Finanskalender 2018 for Nordjyske Bank A/S
21 nov: Transaktioner i henhold til aktietilbagekøbsprogram
21-11-2017 11:28:55

Lundbeck increases its share capital by 116,330 shares (0.0585 % of outstanding shares) as a result of exercise of employee warrants

Valby, Denmark, 2017-11-21 11:28 CET (GLOBE NEWSWIRE) --

Valby, Denmark, 21 November 2017 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 581,650 as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following prices per share of nominally DKK 5: 6,844 shares at DKK 97, 4,374 shares at DKK 113, 5,112 shares at DKK 121 and 100,000 shares at DKK 156.16. Proceeds to the company are DKK 17,392,682 (approximately USD 2.8 million). The increase corresponds to approximately 0.0585 % of the company's share capital.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares shall give rights to dividends and other rights in relation to the company from the time of registration of the capital increase. The new shares will be listed on NASDAQ OMX Copenhagen after registration with the Danish Business Authority.

Lundbeck's current share capital amounts to DKK 994,657,390. The capital increase is expected to be finalized shortly and the total number of voting rights and the total share capital will after the capital increase be:

 

Number of shares

(nominal value DKK 5)

Nominal value of shares

(DKK)

           Number of votes               

199,047,808

995,239,040

199,047,808

    

Lundbeck contacts

Investors:

Media:

 

 

Palle Holm Olesen

Mads Kronborg

Vice President, Investor Relations

Senior Director, Corp. Communication

palo@lundbeck.com

mavk@lundbeck.com

+45 30 83 24 26

+45 36 43 40 00

    

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 15.6 billion in 2016 (EUR 2.1 billion; USD 2.2 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.

 

Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.

Vedhæftet fil: Capital Increase_UK_PDF.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 maj
 
Hej,   Jeg har været herinde i dette forum siden 2010, og har fulgt mange debatører, men en af dem s..
28
17 maj
PNDORA
Jeg personligt mener at en stor del af skribenterne her på forum og markedet som helhed overreagerer..
17
16 maj
PNDORA
Pandora dykkede fordi der manglede 60 millioner i omsætning ud af 1.500 millioner. Det er jo helt gr..
16
19 maj
PNDORA
Pandora realiserede i Q1 2018 en omsætning, som var 44 mDKK lavere end 1Q 2017, såfremt valutakurser..
14
17 maj
NOVO-B
Trump fik fortalt at PBM'ernes rabatsystem er taget for fremskaffelse af lavere priser til patienter..
14
18 maj
DANSKE
Kongsmart, Jensen og Pedersen var de 3 sidste kandidater til en højt betroet post i banken. De mangl..
13
15 maj
VELO
Har lyttet til det nu. Ikke så meget nyt, men bider mærke i, at Envarsus bliver mere og mere en fast..
13
14 maj
VELO
Nu begynder Veloxis at levere varen. Det er klart, at med en vækst 142% i omsætning i forhold til Q1..
13
14 maj
NOVO-B
Nu vil jeg ikke bruge meget tid på dit "Sikken dog noget sludder"  udover, at det er klart, at du ik..
13
19 maj
PNDORA
Når nu det kan være så svært, at tolke shortere, og andre på markedet, så kan det være en god ide, a..
12

Møns Bank Q1: Lille løft på bundlinjen

18-05-2018 13:48:49
Møns Bank kom ud af første kvartal med en stærkere bundlinje, men i store træk resultater, der minder meget om samme periode året før. Forventningerne om et overskud før skat på 20-30 mio. kr. i hele 2018 fastholdes.I første kvartal fik Møns Bank et overskud før skat på 10,7 mio. kr. mod 10 mio. kr. i samme periode sidste år. Dermed er banken allerede over halvvejs i forhold til at nå den nedre en..

Rockwool/CEO: Gode markeder, tiltag og let sammenligning bag fremgang

18-05-2018 09:22:44
Rockwool er kommet flyvende fra start i 2018 og kan fremvise stærk vækst på alle hovedpunkter i det regnskab for første kvartal, som isoleringskoncernen offentliggjorde fredag. Lette sammenligningstal bidrager til billedet, men derudover spiller stærke markeder, prisjusteringer og effektivitesforbedringer ind, siger Rockwools administrerende direktør, Jens Birgersson, i et interview med Ritzau Fin..

Aktier/tendens: Mærsk fortsætter i negativ fokus på ellers positiv dag

18-05-2018 08:26:19
A.P. Møller-Mærsk fik en grum dag torsdag med store fald i aktiekurserne - og det ser ikke ud til, at stormen er drevet over for denne gang for koncernen. Med avisoverskrifter som "Søren Skous nødplan får hårde odds", "Mærsk skuffer fælt" og "Investorerne er ikke begejstrede for Mærsks bud på fremtiden" kan fokus endnu en gang være rettet mod aktierne i koncernen, når handlen starter fredag morgen..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. maj 2018 00:17:58
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180515.2 - EUROWEB3 - 2018-05-22 00:17:58 - 2018-05-22 00:17:58 - 1 - Website: OKAY